{"nctId":"NCT01551056","briefTitle":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","startDateStruct":{"date":"2012-03"},"conditions":["Allergic Conjunctivitis"],"count":91,"armGroups":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL","interventionNames":["Drug: AC-170 0.24%"]},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AC-170 0%"]}],"interventions":[{"name":"AC-170 0.24%","otherNames":[]},{"name":"AC-170 0%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* positive bilateral conjunctival allergen challenge (CAC) reaction\n\nExclusion Criteria:\n\n* known contraindications or sensitivities to the study medication or its components\n* any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters\n* use of disallowed medication during the period indicated prior to the enrollment or during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"0.886"},{"groupId":"OG001","value":"2.34","spread":"0.720"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.910"},{"groupId":"OG001","value":"2.50","spread":"0.644"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.944"},{"groupId":"OG001","value":"2.22","spread":"0.875"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.638"},{"groupId":"OG001","value":"2.18","spread":"0.979"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.691"},{"groupId":"OG001","value":"2.31","spread":"0.980"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.783"},{"groupId":"OG001","value":"2.10","spread":"0.998"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.771"},{"groupId":"OG001","value":"1.94","spread":"0.796"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"0.777"},{"groupId":"OG001","value":"2.02","spread":"0.788"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.780"},{"groupId":"OG001","value":"1.98","spread":"0.759"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"0.728"},{"groupId":"OG001","value":"2.05","spread":"0.714"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.667"},{"groupId":"OG001","value":"2.13","spread":"0.736"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"0.644"},{"groupId":"OG001","value":"2.18","spread":"0.762"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"0.786"},{"groupId":"OG001","value":"1.82","spread":"0.832"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"0.825"},{"groupId":"OG001","value":"1.96","spread":"0.756"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.821"},{"groupId":"OG001","value":"1.93","spread":"0.771"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"0.810"},{"groupId":"OG001","value":"1.90","spread":"0.645"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.789"},{"groupId":"OG001","value":"1.99","spread":"0.769"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":"0.806"},{"groupId":"OG001","value":"2.06","spread":"0.767"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.719"},{"groupId":"OG001","value":"1.94","spread":"0.798"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.781"},{"groupId":"OG001","value":"2.07","spread":"0.775"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"0.768"},{"groupId":"OG001","value":"2.03","spread":"0.764"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.804"},{"groupId":"OG001","value":"1.96","spread":"0.725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":"0.791"},{"groupId":"OG001","value":"2.10","spread":"0.793"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.758"},{"groupId":"OG001","value":"2.16","spread":"0.778"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.461"},{"groupId":"OG001","value":"0.70","spread":"0.550"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.605"},{"groupId":"OG001","value":"1.01","spread":"0.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.605"},{"groupId":"OG001","value":"1.05","spread":"0.802"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.501"},{"groupId":"OG001","value":"0.97","spread":"0.702"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.685"},{"groupId":"OG001","value":"1.42","spread":"0.895"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.736"},{"groupId":"OG001","value":"1.53","spread":"0.950"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.73"},{"groupId":"OG001","value":"1.1","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.89"},{"groupId":"OG001","value":"1.3","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.97"},{"groupId":"OG001","value":"1.2","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.65"},{"groupId":"OG001","value":"0.9","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.74"},{"groupId":"OG001","value":"1.1","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.79"},{"groupId":"OG001","value":"1.1","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.69"},{"groupId":"OG001","value":"1.1","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.89"},{"groupId":"OG001","value":"1.2","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.98"},{"groupId":"OG001","value":"1.1","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"Tearing at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.57"},{"groupId":"OG001","value":"1.0","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.87"},{"groupId":"OG001","value":"0.8","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.88"},{"groupId":"OG001","value":"0.8","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.89"},{"groupId":"OG001","value":"1.4","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.03"},{"groupId":"OG001","value":"1.3","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.10"},{"groupId":"OG001","value":"1.4","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.64"},{"groupId":"OG001","value":"1.1","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.73"},{"groupId":"OG001","value":"1.0","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.82"},{"groupId":"OG001","value":"1.0","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.72"},{"groupId":"OG001","value":"1.0","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.03"},{"groupId":"OG001","value":"1.0","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.95"},{"groupId":"OG001","value":"1.1","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritis at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.53"},{"groupId":"OG001","value":"0.7","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.59"},{"groupId":"OG001","value":"0.8","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.73"},{"groupId":"OG001","value":"0.7","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.69"},{"groupId":"OG001","value":"1.0","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.13"},{"groupId":"OG001","value":"1.3","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.16"},{"groupId":"OG001","value":"1.5","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.51"},{"groupId":"OG001","value":"1.0","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.66"},{"groupId":"OG001","value":"1.1","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.69"},{"groupId":"OG001","value":"1.0","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.94"},{"groupId":"OG001","value":"1.3","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.04"},{"groupId":"OG001","value":"1.5","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.15"},{"groupId":"OG001","value":"1.4","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.60"},{"groupId":"OG001","value":"1.0","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.86"},{"groupId":"OG001","value":"1.2","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.10"},{"groupId":"OG001","value":"1.2","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)","description":"A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"84.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability of Study Medication at Visit 3A","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.44"},{"groupId":"OG001","value":"0.9","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.37"},{"groupId":"OG001","value":"0.6","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.29"},{"groupId":"OG001","value":"0.6","spread":"0.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Conjunctival haemorrhage","Visual acuity reduced","Hordeolum","Nasopharyngitis","Oropharyngeal Pain"]}}}